Strand AI
Strand AI uses foundation models to predict missing patient data, helping pharma teams select better trial candidates and bring effective drugs to market faster
- Use Cases
- Not listed yet
- Pricing
- Custom
- Platforms
- Not listed yet
Overview
Unlock the Full Potential of Your Clinical Trials with Predictive Multimodal Patient Data
Strand AI helps life sciences teams overcome the limitations of incomplete patient data, a major contributor to the 90% failure rate of clinical trials, by predicting missing biological modalities from existing data, enabling more accurate patient selection and biomarker discovery.
Details
Key Features
- Rescue incomplete cohorts by predicting missing modalities, reducing the need for additional invasive and expensive assays
- Generate high-quality multimodal patient data, including gene expression, proteomics, and spatial transcriptomics, from routinely collected samples
- Unlock rare disease cohorts by filling in missing modalities, enabling more effective model training and biomarker discovery
- Impute unmeasured biomarkers across entire cohorts, surfacing predictive signatures without the need for re-acquisition
Best For
- Life sciences teams running clinical trials and seeking to improve patient selection and biomarker discovery
- Researchers working with rare disease cohorts and requiring more comprehensive and accurate data
- Biopharmaceutical companies aiming to reduce the cost and time associated with clinical trials and improve drug development outcomes
Read full editorial notes
Key Features
Rescue incomplete cohorts by predicting missing modalities, reducing the need for additional invasive and expensive assays
Generate high-quality multimodal patient data, including gene expression, proteomics, and spatial transcriptomics, from routinely collected samples
Unlock rare disease cohorts by filling in missing modalities, enabling more effective model training and biomarker discovery
Impute unmeasured biomarkers across entire cohorts, surfacing predictive signatures without the need for re-acquisition
Streamline clinical trial workflows by skipping the expensive and time-consuming process of acquiring every modality for every patient
Ideal For
Life sciences teams running clinical trials and seeking to improve patient selection and biomarker discovery
Researchers working with rare disease cohorts and requiring more comprehensive and accurate data
Biopharmaceutical companies aiming to reduce the cost and time associated with clinical trials and improve drug development outcomes
Ideal for
Keep researching Strand AI
Explore relevant products with a similar category, audience, or use case.
Launched
Ownership
If this is your product, contact us and we can help transfer it to you.
